zinc gluconate

ApprovedSmall molecule

Johnson & Johnson

zinc gluconate is one of 120 small molecule programs targeting Noise-Induced Hearing Loss. It is currently in Approved.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Noise-Induced Hearing LossActive, not recruiting

HyperbilirubinemiaActive, not recruiting

PneumoniaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungActive, not recruiting

Prediabetic StateRecruiting

Noise-Induced Hearing LossPreclinical

Active, not recruiting

HyperbilirubinemiaPhase 1/Phase 2

Active, not recruiting

PneumoniaPhase 2/Phase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Active, not recruiting

Prediabetic StateApproved

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

zinc gluconate

Johnson & Johnson

Approved

10 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

REGN2810

Regeneron

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

ApprovedRecruiting

Prediabetic State

NCT05835037

Q2 2030

Phase 2Active, not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140

Clinical

Trials by Indication[1]

APL1 trial

Effect of Zinc on Barrett's Metaplasia

Unknown status·MMain Line Health·Phase 1·NCT01984580·120 enrolled

Cardiovascular1 trial

Zinc Effect on Inflammation and Cardiovascular Risk in HIV

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 1·NCT05085834·95 enrolled

Pneumonia1 trial

Zinc Intervention in Elderly for Prevention of Pneumonia

Completed·TTufts University·Phase 2/3·NCT05527899·105 enrolled

Hyperbilirubinemia1 trial

Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial

Completed·—·Phase 1/2·NCT00692224·294 enrolled

Noise-Induced Hearing Loss1 trial

Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss

Completed·—·N/A·NCT02951715·20 enrolled

5 more indications

Olfactory Dysfunction1 trial

The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction

Not yet recruiting·TTaichung Veterans General Hospital·Phase 3·NCT06290219·80 enrolled

Low Birth Weight1 trial

Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease

Completed·SSociety for Applied Studies·Phase 3·NCT00495690·2,012 enrolled

Prediabetic State1 trial

Clinical and Nutrigenetic Assessment of Zinc in Participants With Prediabetes

Recruiting·UUniversity of Maryland, Baltimore·Approved·NCT05835037·200 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06120140·305 enrolled

Unspecified1 trial

The Individual Therapy for Patients With Wilson's Disease

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03957720·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for zinc gluconate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zinc gluconate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zinc gluconate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson

zinc gluconate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2030

Trials by Indication[1]

APL1 trial

Cardiovascular1 trial

Pneumonia1 trial

Hyperbilirubinemia1 trial

Noise-Induced Hearing Loss1 trial

Olfactory Dysfunction1 trial

Low Birth Weight1 trial

Prediabetic State1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News